Eligibility Details:  
        Inclusion Criteria:
          -  Participant must have a confirmed diagnosis of adenocarcinoma of the prostate
          -  Participant must have metastatic prostate cancer, as follows: a) nmCRPC: nmCRPC
             diagnosis at any time, documented castration resistance per Prostate Cancer Working
             Group 3 criteria23 (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]),
             Negative for metastases on conventional imaging (computerized tomography, Magnetic
             resonance imaging, bone scans), Prostate specific antigen doubling time (PSADT) less
             than equal to (<=) 12 months within the last 6 months or beginning treatment with
             approved next-generation ARAT for treatment of nmCRPC b) Metastatic castrate-sensitive
             prostate cancer (mCSPC): new mCSPC diagnosis in the past 6 months (can be de novo or
             primary progressive recurrent following local radical therapy), documented metastatic
             prostate cancer, no more than 12 months of androgen deprivation therapy (ADT) in any
             setting, no more than 6 months of systemic treatment for mCSPC (example, approved next
             generation androgen receptor targeted therapy or chemotherapy]), c) Metastatic
             castrate-resistant prostate cancer (mCRPC): mCRPC diagnosis at any time, documented
             metastatic prostate cancer, documented castration resistance per Prostate Cancer
             Working Group 2 criteria (elevated prostate specific antigen [PSA] despite
             testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nano moles per
             liter{nmol/L}]), the first treatment for mCRPC was started in the past 6 months or is
             scheduled to begin
          -  Participant must have a life expectancy of more than 6 months
          -  Participant must sign (and/or their legally acceptable representative, if applicable)
             a participation agreement/informed consent form (ICF) allowing data collection and
             source data verification in accordance with local requirements and/or sponsor policy
        Exclusion Criteria:
          -  At the time of screening, patient is currently enrolled in other Janssen sponsored
             clinical study (any indication) or an interventional clinical trial investigating a
             non Health Canada approved drug and/or procedure for the treatment and/or monitoring
             of prostate cancer (Janssen or non-Janssen company sponsored)
          -  Participant is currently enrolled in any observational study sponsored or managed by a
             Janssen company